What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

Please provide your email address to receive an email when new articles are posted on . Delaying follow-up after receipt of positive lung cancer screening findings was relatively common. Patients with ...

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who ...

Please provide your email address to receive an email when new articles are posted on . Patients with false-positive lung cancer screening findings did not often undergo Invasive procedures. Procedure ...

Alecensa achieved a 4-year OS rate of 98.4% in resected ALK-positive early-stage NSCLC, outperforming chemotherapy. The ALINA study showed a 65% reduction in disease recurrence or death risk with ...

Stage 3 non-small cell lung cancer has spread to nearby tissues and lymph nodes but not to more distant tissues. Most people with this stage have lung cancer symptoms. Treatment can depend on several ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

While medical headlines often focus on the biochemical underpinnings of disease, our body's biomechanics are equally crucial. A recent study explores how hypertension affects lung function, revealing ...